This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Source：MarketWatch
Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.